NASDAQ : OCS
Oculis Holding AG — Key statistics
Healthcare · Biotechnology · Switzerland
Last price 8.26 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 509.91M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 493.86M |
| Enterprise Value | 214.42M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 61.73M |
| Shares Outstanding | 61.73M |
| Shares Change (YoY) | +23.50% |
| Shares Change (QoQ) | +4.02% |
| Owned by Insiders (%) | 3.87% |
| Owned by Institutions (%) | 35.29% |
| Float | 52.39M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 351.24 |
| Forward PS | 956.41 |
| PB Ratio | 1.88 |
| P/TBV Ratio | 2.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 158.76 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.35 |
| Quick Ratio | 8.24 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -97.43 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -43.70% |
| Return on Assets (ROA) | -24.95% |
| Return on Invested Capital (ROIC) | -29.45% |
| Return on Capital Employed (ROCE) | -38.77% |
| Weighted Average Cost of Capital (WACC) | 5.84% |
| Revenue Per Employee | $24,196 |
| Profits Per Employee | -$1.63M |
| Employee Count | 60 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -323,020 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.27 |
| 52-Week Price Change | -57.47% |
| 50-Day Moving Average | 9.65 |
| 200-Day Moving Average | 18.74 |
| Relative Strength Index (RSI) | 44.64 |
| Average Volume (20 Days) | 295,424 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.79M |
| Short Previous Month | 1.77M |
| Short % of Shares Out | 2.89% |
| Short % of Float | 3.41% |
| Short Ratio (days to cover) | 5.57 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 1.45M |
| Gross Profit | -68.76M |
| Operating Income | -106.71M |
| Pretax Income | -98.33M |
| Net Income | -98.01M |
| EBITDA | -106.41M |
| EBIT | -106.71M |
| Loss Per Share | -$1.72 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 282.58M |
| Total Debt | 3.15M |
| Net Cash | 279.43M |
| Net Cash Per Share | $4.53 |
| Equity (Book Value) | 271.46M |
| Book Value Per Share | 4.40 |
| Working Capital | 253.89M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -80.13M |
| Capital Expenditures | -223,298 |
| Depreciation & Amortization | 302,611 |
| Net Borrowing | -540,551 |
| Free Cash Flow | -80.35M |
| FCF Per Share | -$1.30 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -7,350.81% |
| Pretax Margin | -6,773.31% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -23.50% |
| Shareholder Yield | -23.50% |
| Earnings Yield | -21.44% |
| FCF Yield | -15.76% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $37.26 |
| Price Target Difference | 365.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | 228.90% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 16.53 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |